Publication | Closed Access

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Surgical OncologyMedicineMelanomaImmunologyClinical TrialsImmune Checkpoint InhibitorVersus PlaceboImmunotherapyOncologyFinal Results